Correction to: Homologous targeting nanoparticles for enhanced PDT against osteosarcoma HOS cells and the related molecular mechanisms.

Correction to: Journal of Nanobiotechnology (2022) 20:83 https://doi.org/10.1186/s12951-021-01201-y

Following publication of the original article [1], the authors identified an error in Figs. 2 and 7. The corrected Figs. 2, 7 and the figure caption are given in this correction.

Fig. 2

Biosafety of the MH-PLGA-IR780 NPs. A Relative viability (%) of HOS cells after coincubation with a wide range of NPs concentrations. B Relative viability (%) of HOS cells after coincubation with MH-PLGA-IR780 NPs (PLGA: 0.2 mg/mL) at prolonged time points. (The data are presented as the mean ± SD). C, D Blood indexes (routine blood and biochemistry) and H&E staining of the main organs (heart, liver, spleen, lung and kidney) of BALB/c nude mice were collected at 0, 1, 7, 14, and 28 days after post injection of MH-PLGA-IR780 NPs (n = 5). The scale bars represent 100 µm

Fig. 7

Evaluation of apoptosis and ferroptosis. A, B Induction of apoptosis in HOS cells (stained with annexin V-FITC/PI) after various treatments by FC analysis. (The data are presented as the mean ± SD values; n = 3, *p < 0.05, **p < 0.01.) C–E Changes in Δψm in HOS cells stained with JC-1 after various managements, as observed via CLSM and FC. (The data are presented as the mean ± SD values; n = 3, *p < 0.05, **p < 0.01.) The scale bars represent 100 µm. F The expression levels of cell apoptosis-related proteins were measured by western blot analysis. G, H The excessive production of LPO and Lipid ROS in HOS cells after targeted PDT as measured by CLSM and FC. The scale bars represent 100 µm. I The morphology of mitochondria after various treatments as observed by TEM. The scale bars represent 1 µm

All the authors apologize for these errors and all the data herein are accurate and reproducible.

The original article has been revised.